Loading...
Loading...
India's metronidazole imports from FRANCE total $276 across 1 shipments from 1 foreign suppliers. CUBIC PHARMACEUTICALS LTD. leads with $276 in import value; the top 5 suppliers together control 100.0% of this origin. Leading Indian buyers include XYLOPIA LABS PRIVATE LIMITED. This corridor reflects India's pharmaceutical import demand for metronidazole โ a concentrated sourcing relationship with select suppliers from FRANCE.

CUBIC PHARMACEUTICALS LTD. is the leading Metronidazole supplier from FRANCE to India, with import value of $276 across 1 shipments. The top 5 suppliers โ CUBIC PHARMACEUTICALS LTD. โ collectively account for 100.0% of total import value from this origin.
Ranked by import value (USD) ยท Indian Customs (DGFT) data
| # | Supplier | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | CUBIC PHARMACEUTICALS LTD. | $276 | 1 | 100.0% |
Ranked by import value (USD)
| # | Buyer | Value (USD) | Shipments | Share |
|---|---|---|---|---|
| 1 | XYLOPIA LABS PRIVATE LIMITED | $276 | 1 | 100.0% |
Visual overview of India's metronidazole FRANCE to India import corridor โ top suppliers, destinations, pricing, and trade routes
FRANCE โ India trade corridor intelligence
The France to India trade corridor for pharmaceutical imports, including Metronidazole formulations, is currently stable. Major ports such as Jawaharlal Nehru Port Trust (JNPT), Chennai, and Mundra are operating efficiently, with minimal congestion. Freight rates have remained consistent over the past year, and the exchange rate between the Indian Rupee (INR) and the Euro has shown moderate fluctuations, not significantly impacting the cost of imports. Logistics providers report timely deliveries, and there are no significant disruptions in the supply chain.
The Indian government's Production Linked Incentive (PLI) scheme aims to boost domestic manufacturing and reduce reliance on imports. While this initiative encourages local production, it may impact the import of finished pharmaceutical formulations, including Metronidazole. Import substitution policies are being evaluated to determine their effectiveness in reducing import dependency without compromising product quality and availability. The balance between promoting self-reliance and meeting domestic demand for specialized formulations remains a key consideration for policymakers.
India and France share a robust trade relationship, with ongoing negotiations to enhance economic cooperation. Discussions include potential Free Trade Agreements (FTAs) and mutual recognition of Good Manufacturing Practices (GMP) to facilitate smoother pharmaceutical trade. These efforts aim to streamline regulatory processes, reduce trade barriers, and promote the exchange of high-quality pharmaceutical products between the two nations.
The landed cost of importing Metronidazole formulations from France to India includes several components:
Per-unit estimates can be calculated by summing these components and dividing by the total number of units imported. It's essential to account for currency exchange rates and potential fluctuations in freight costs when calculating the final landed cost.
CDSCO registration, import licensing, and quality testing requirements
Importing finished pharmaceutical formulations containing Metronidazole into India requires compliance with the Drugs and Cosmetics Act, 1940, and the Drugs and Cosmetics Rules, 1945. The Central Drugs Standard Control Organization (CDSCO) mandates that all imported drugs possess a valid import license issued under Form 10. Additionally, the foreign manufacturer must be registered with CDSCO under Form 41. The Indian importer must obtain an Importer Exporter Code (IEC) from the Directorate General of Foreign Trade (DGFT). The application process involves submitting detailed product information, manufacturing licenses, and authorization letters from the foreign manufacturer. The timeline for obtaining these approvals can vary but typically ranges from 3 to 6 months, depending on the completeness of the application and regulatory processing times.
Imported pharmaceutical formulations containing Metronidazole must undergo quality testing at CDSCO-approved laboratories to ensure compliance with Indian standards. Each batch requires a Certificate of Analysis (CoA) confirming adherence to the Indian Pharmacopoeia. Stability data, particularly for ICH Zone IV conditions, must be provided to demonstrate the product's shelf-life under India's climatic conditions. Port inspections by customs drug inspectors are conducted to verify the authenticity and quality of the imported products. These inspections include sampling and testing, which can extend the clearance time by several days. If a batch fails quality testing, it may be subject to re-exportation, destruction, or other regulatory actions as deemed appropriate by CDSCO.
Between 2024 and 2026, CDSCO has implemented stricter regulations for the importation of pharmaceutical products to enhance drug safety and efficacy. Notably, on April 8, 2025, CDSCO mandated that all imported drugs, including finished formulations containing Metronidazole, must have both import registration and a license. This policy aims to prevent the sale of unapproved or illegal medicines in the Indian market. The introduction of the Production Linked Incentive (PLI) scheme has also impacted the import landscape, encouraging domestic manufacturing and potentially reducing reliance on imports. Bilateral agreements between India and France have facilitated smoother trade relations, with mutual recognition of Good Manufacturing Practices (GMP) and streamlined approval processes for French pharmaceutical products.
Market demand, customs duty structure, and competitive landscape ยท Import duty: 10%
India imports finished Metronidazole formulations primarily due to the demand for specific dosage forms and branded products not manufactured domestically. The domestic production of Metronidazole is substantial; however, certain specialized formulations, such as extended-release tablets or combination therapies, are not produced locally. The market size for Metronidazole formulations in India is significant, with a growing demand driven by the prevalence of infections treatable by Metronidazole. The import dependency is influenced by factors such as patent protections, technological advancements, and the need for high-quality products that meet international standards.
The Basic Customs Duty (BCD) for HS Code 30049022, which covers Metronidazole formulations, is 10%. In addition to BCD, the Social Welfare Surcharge (SWS) is levied at 10% of the BCD, resulting in an effective duty of 11%. The Integrated Goods and Services Tax (IGST) is applicable at 12% on the assessable value, which includes the CIF (Cost, Insurance, and Freight) value plus the BCD and SWS. Anti-dumping duties may apply if the Directorate General of Trade Remedies (DGTR) determines that imports are being dumped in the Indian market. Exemption notifications can reduce or eliminate certain duties; however, no specific exemptions are currently applicable to Metronidazole formulations from France. The total landed duty percentage combines these components, affecting the final cost of imported products.
India sources Metronidazole formulations from France due to the high quality and reliability of French pharmaceutical products. French manufacturers often offer patented formulations and specialized dosage forms that are not available from other suppliers. The competitive advantage of French suppliers includes adherence to stringent quality standards, advanced manufacturing technologies, and a reputation for producing high-quality pharmaceutical products. Other suppliers, such as China, Germany, and the United States, also export Metronidazole formulations to India; however, France's share in this market is notable due to these factors.
Import rationale, competitive comparison, supply chain risk, and procurement strategy
India imports Metronidazole formulations from France due to the availability of patented formulations and specialized dosage forms not produced domestically. French manufacturers offer high-quality products that meet international standards, which is crucial for treating infections effectively. The technological advancements and adherence to stringent quality controls in France provide a competitive edge, making French products desirable in the Indian market.
When compared to other origins such as China, Germany, and the United States, France offers superior quality and reliability in pharmaceutical manufacturing. French products are known for their adherence to international quality standards and innovative formulations. While other countries may offer competitive pricing, France's reputation for quality and consistency makes it a preferred choice for importing Metronidazole formulations into India.
Indian importers face several supply chain risks when sourcing Metronidazole formulations from France, including single-source dependency, currency fluctuations, regulatory changes, quality incidents, and shipping disruptions. To mitigate these risks, importers should consider diversifying their supplier base, closely monitoring currency exchange rates, staying updated on regulatory changes, and establishing contingency plans for potential shipping delays or quality issues.
Answers based on Indian Customs (DGFT) import records compiled by TransData Nexus
The top Metronidazole suppliers from FRANCE to India include CUBIC PHARMACEUTICALS LTD.. The leading supplier is CUBIC PHARMACEUTICALS LTD. with import value of $276 USD across 1 shipments. India imported Metronidazole worth $276 USD from FRANCE in total across 1 shipments.
India imported Metronidazole worth $276 USD from FRANCE across 1 shipments. Data is from Indian Customs (DGFT) records. Values are in USD.
The main Indian buyers of Metronidazole sourced from FRANCE include XYLOPIA LABS PRIVATE LIMITED. The largest buyer is XYLOPIA LABS PRIVATE LIMITED with $276 in imports across 1 shipments.
The total value of Metronidazole imports from FRANCE to India is $276 USD, across 1 shipments and 1 foreign suppliers. Data source: Indian Customs (DGFT).
Data sourced from Indian Customs (DGFT) records. Verify regulatory and trade status with the agencies above.
Pharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormareAll trade data is sourced from Indian Customs (DGFT) official shipping bill records โ the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
1 Verified Shipments
1 suppliers, 1 buyers tracked
Expert-Reviewed
By pharmaceutical trade specialists